(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 September 2006 (28.09.2006)

PCT

(10) International Publication Number
WO 2006/100109 A1

(51) International Patent Classification:
A61K 39/145 (2006.01)

(21) International Application Number:
PCT/EP2006/002836

(22) International Filing Date: 21 March 2006 (21.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0506001.7	23 March 2005 (23.03.2005)	GB
0506000.9	23 March 2005 (23.03.2005)	GB
0505998.5	23 March 2005 (23.03.2005)	GB
0505989.4	23 March 2005 (23.03.2005)	GB
0506004.1	23 March 2005 (23.03.2005)	GB
0510589.5	24 May 2005 (24.05.2005)	GB
0510591.1	24 May 2005 (24.05.2005)	GB
0510593.7	24 May 2005 (24.05.2005)	GB
0510596.0	24 May 2005 (24.05.2005)	GB
0510598.6	24 May 2005 (24.05.2005)	GB
0603789.9	24 February 2006 (24.02.2006)	GB
0603788.1	24 February 2006 (24.02.2006)	GB
0603790.7	24 February 2006 (24.02.2006)	GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HANON, Emmanuel, Jules** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **STEPHENNE, Jean** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **CREPIN, Carine**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** USE OF AN INFLUENZA VIRUS AN OIL-IN-WATER EMULSION ADJUVANT TO INDUCE CD4 T-CELL AND/OR IMPROVED B-MEMORY CELL RESPONSE

(57) **Abstract:** The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and optionally 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to influenza antigens, and to methods of preparation, wherein the oil in water emulsion comprises a sterol, a metabolisable oil and an emulsifying agent.

WO 2006/100109 A1